THESE Many Companies Have filed draft papers for IPOs in Till May 2025

New Delhi: Despite ongoing world marketplace volatility, just about 90 firms have submitted draft purple herring prospectuses (DRHPs) with the Securities and Exchange Board of India (SEBI) between January and May 2025, signalling persevered passion in going public. 

Data from the SEBI web page finds that January noticed the best possible process, with 28 firms submitting draft papers, adopted by way of 15 in February, 11 in March, 24 in April, and 12 to this point in May.

The surge in DRHP filings comes at a time when the true choice of preliminary public choices (IPOs) hitting the marketplace has been considerably decrease in comparison to the similar duration final yr.

Only 9 firms have made their debut at the mainboard section between January and May this yr, in comparison to over 25 in the similar duration in 2024.

Among the notable names that experience filed for IPOs this yr are Canara HSBC Life Insurance, Canara Robeco Asset Management Company, Anand Rathi Share and Stock Brokers, and WeWork India.

Filing a DRHP is step one for corporations aiming to lift finances via an IPO. The record outlines key data equivalent to monetary efficiency, trade operations, dangers, and different disclosures required by way of the SEBI.

While the passion in IPOs stays secure, the susceptible record momentum displays broader considerations brought about by way of world uncertainties.

The Indian fairness markets have skilled vital fluctuations in 2025, impacted by way of geopolitical tensions and tariff-related measures, specifically from the United States.

Since the start of the yr, the Sensex has posted a go back of 2.73 in keeping with cent, whilst the Nifty has won round 3 in keeping with cent — each reflecting wary optimism amid a turbulent world surroundings.

Meanwhile, IPOs within the biopharmaceutical sector noticed a pointy rebound in 2024, leaping 68.4 in keeping with cent year-on-year (YoY) to $8.52 billion, in line with a brand new file by way of InternationalData.

A complete of 50 IPOs have been finished globally within the sector this yr, up from $5.06 billion raised in 2023, making it the most powerful yr for biopharma IPOs since 2021, the file stated.